In a report released today, Justin Smith from Bernstein maintained a Buy rating on GlaxoSmithKline, with a price target of £21.70. The company’s shares closed today at p1,373.00. Take advantage of ...

GlaxoSmithKline plc (UK) (($GB:GSK)) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) is ...

GlaxoSmithKline plc (UK) (($GB:GSK)) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) is ...

Use of belimumab prior to vs after initiating immunosuppressants was linked to faster OGC tapering and fewer disease flares among patients with SLE.

Although obinutuzumab has not yet received FDA approval in lupus nephritis, findings from a recent survey conducted by ...

GSK will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology and inflammation.

Manufacturing GSK telegraphs 150 layoffs amid plan to transfer vaccine manufacturing from Massachusetts site By Fraiser Kansteiner Jul 22, 2025 8:53am GSK drug manufacturing vaccine manufacturing ...

Chris Ratcliffe/Bloomberg British biopharmaceutical company GlaxoSmithKline will lay off 150 employees in its Cambridge operations by the end of March 2026, the company said in a notice to the state.

As GSK pursues biotech tie-ups and reinvests in internal R&D capabilities, a "very limited number" of science roles will be eliminated.

The FDA has approved Benlysta for SC administration using an autoinjector in patients 5 years of age and older with active LN.

Glaxosmithkline's Benlysta autoinjector earns FDA approval for treating lupus nephritis in kids—first at-home option.